Related Experiment Video
Updated: Dec 13, 2025

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.2K
Machine-Learning Based Model to Improve Insulin Bolus Calculation in Type 1 Diabetes Therapy
IEEE Transactions on Bio-Medical Engineering
|August 4, 2020
Summary
A new machine learning model, LASSO Q, improves mealtime insulin boluses (MIB) for type 1 diabetes (T1D) management. This model uses continuous glucose monitoring (CGM) data to reduce hypo/hyperglycemic episodes, enhancing patient safety.
Area of Science:
- Endocrinology and Metabolism
- Artificial Intelligence in Healthcare
- Biomedical Data Science
Background:
- Type 1 diabetes (T1D) management relies on accurate mealtime insulin boluses (MIB).
- Current standard formulas (SF) for MIB do not account for glucose rate-of-change (ΔG), leading to glycemic variability.
- Continuous glucose monitoring (CGM) data offers potential for more precise MIB calculations.
Purpose of the Study:
- To develop and evaluate machine learning models for improved MIB calculation in T1D.
- To incorporate CGM-derived glucose rate-of-change (ΔG) into MIB dosage algorithms.
- To compare the performance of novel models against standard formulas and existing literature methods.
Main Methods:
- Four machine learning models, including multiple linear regression (MLR) and LASSO, were developed for MIB calculation.
- Models were validated using the UVa/Padova T1D simulator in various mealtime scenarios.
- Retrospective analysis of 218 real-world glycemic traces was conducted to confirm findings.
Main Results:
- All developed models outperformed existing MIB calculation techniques.
- The LASSO regression with quadratic terms (LASSO Q) model demonstrated superior performance.
- LASSO Q significantly reduced bolus estimation error (0.86 U vs. 1.45 U for SF) and hypoglycemia incidence (35.93% vs. 44.41% for SF).
Conclusions:
- Machine learning frameworks can effectively develop improved MIB calculation models using CGM and ΔG data.
- The proposed LASSO Q model offers enhanced glycemic control compared to SF and other methods.
- Implementing the LASSO Q model for MIB dosage may reduce adverse glycemic events in T1D therapy.
Related Concept Videos
Insulin: Dosing Regimen and Adverse Effects
542
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
542
Diabetes Mellitus: Overview and Type I Subtype
4.7K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.7K
Diabetes: Management and Pharmacotherapy
766
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
766
Insulin Formulations: Types and Delivery
534
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
534
Insulin: Biosynthesis, Chemistry, and Preparation
1.0K
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
1.0K
One-Compartment Open Model for IV Bolus Administration: General Considerations
566
The one-compartment model is a pharmacokinetic tool that models the body as a single, uniform compartment, facilitating the understanding of drug distribution and elimination. This model is particularly beneficial for intravenous (IV) bolus administration, where the drug rapidly circulates throughout the body.
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...
566

